Semaglutide News and Research

Latest Semaglutide News and Research

Isis Pharmaceuticals reports positive data from ISIS-GCGRRx Phase 2 study in patients with type 2 diabetes

Isis Pharmaceuticals, Inc. announced today positive data from a Phase 2 study of ISIS-GCGRRx in patients with type 2 diabetes uncontrolled on stable metformin therapy.

14 May 2014

Patients with Parkinson's disease show improvements after exenatide therapy

Follow-Up Study Published in the Journal of Parkinson's Disease Supports an Earlier "Proof of Concept" Trial. A follow-up study of patients with Parkinson's disease (PD) who participated in an earlier "proof of concept" clinical trial using exenatide showed that improvements persisted twelve months after discontinuing exenatide therapy.

9 May 2014

FDA approves GSK's Tanzeum as once-weekly treatment for type 2 diabetes

GlaxoSmithKline plc today announced that the US Food and Drug Administration has approved Tanzeum (albiglutide) for injection, for subcutaneous use, as a once-weekly treatment for type 2 diabetes. Tanzeum has been approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

16 Apr 2014

Common treatment for type 2 diabetes could cause longer-than-normal periods of hypoglycemia

Researchers at the University of Adelaide have discovered that a common treatment for people with type 2 diabetes could cause longer-than-normal periods of the low blood sugar reaction hypoglycemia, which may result in increased health risks to people with diabetes.

9 Apr 2014

Adocia announces positive final results for first clinical trial of BioChaperone Combo

Adocia announces today positive final results for the first clinical trial on its innovative formulation combining insulin analog glargine (Lantus, Sanofi), the gold standard basal insulin, with a rapid-acting insulin analog, lispro (Humalog, Eli Lilly) using Adocia's BioChaperone technology.

20 Mar 2014

New sweetener from tequila plant may aid diabetes, weight loss

A sweetener created from the plant used to make tequila could lower blood glucose levels for the 26 million Americans and others worldwide who have type 2 diabetes and help them and the obese lose weight, researchers said here today.

18 Mar 2014

DCR enters into agreement with Pyxant Labs for early clinical trials

DaVita Clinical Research, a specialty contract research organization with services spanning the full spectrum of drug and device development, announced today that it has entered into an agreement through which Pyxant Labs Inc. will provide bioanalytical laboratory services for DCR's early clinical trials.

12 Feb 2014

Vivaldi Biosciences inks agreement with NIAID to evaluate LAIV candidates against influenza A

Vivaldi Biosciences Inc., a clinical-stage biotechnology company developing live attenuated influenza vaccines against seasonal and pandemic influenza, today announced that it has signed a Cooperative Research and Development Agreement with the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, to generate and evaluate in preclinical studies LAIV candidates against influenza A(H7N9).

21 Jan 2014

Macrophages invade diabetic pancreatic tissue during early stages of type 2 diabetes

As people's waistlines increase, so does the incidence of type 2 diabetes. Now scientists have a better understanding of exactly what happens in the body that leads up to type 2 diabetes, and what likely causes some of the complications related to the disease. Specifically, scientists from Denmark have found that in mice, macrophages, a specific type of immune cell, invade the diabetic pancreatic tissue during the early stages of the disease.

2 Jan 2014

Oramed Pharmaceuticals to purchase $15,800,000 shares in registered direct offering

Oramed Pharmaceuticals Inc., a developer of oral drug delivery systems, today announced that it has entered into definitive agreements with investors to purchase an aggregate of 1,580,000 shares of common stock at a price of $10.00 per share in a registered direct offering.

26 Dec 2013

Artificial sweetener sucralose has biological effects

The artificial sweetener sucralose is a biologically active compound according to an extensive review published by Taylor & Francis in the recent issue of Journal of Toxicology and Environmental Health, Part B: Critical Reviews. "Sucralose, A Synthetic Organochlorine Sweetener: Overview Of Biological Issues" authored by Susan S. Schiffman, PhD, an internationally known sweetener researcher and Kristina I. Rother, MD, MHSc, of the National Institutes of Health (NIH), summarizes the biological properties of sucralose based on hundreds of archival, peer-reviewed scientific journal publications.

13 Dec 2013

Ascend, 3M partner to develop and evaluate novel immunotherapy treatments for cancer

Ascend Biopharmaceuticals today announces that is has entered into an agreement with 3M Drug Delivery Systems to evaluate 3M’s Toll-Like Receptor 7/8 (TLR7/8) agonist 3M-051 in combination with Ascend’s proprietary cancer vaccine technology. The collaboration will support the creation and preclinical assessment of novel immunotherapy treatments to be potentially used for a number of different solid tumor types.

29 Nov 2013

GLP-1 hormone can predict metabolic efficacy of gastric bypass

The sensitivity of the GLP-1 hormone, which is secreted by the gastrointestinal tract, can predict the metabolic efficacy of a gastric bypass. The use of a GLP1 challenge could thus function as a novel predictive biomarker for personalized treatment of type 2 diabetes and obesity.

8 Nov 2013

New therapeutic approach for treating type 2 diabetes

Scientists from the Helmholtz Zentrum München (HMGU) and the Technische Universität München (TUM), together with scientists in the USA, have developed a new therapeutic approach for treatment of type 2 diabetes.

31 Oct 2013

Scientists develop new therapeutic approach for treatment of type 2 diabetes

Scientists from the Helmholtz Zentrum Muenchen and the Technische Universitaet Muenchen, together with scientists in the USA, have developed a new therapeutic approach for treatment of Type 2 diabetes. A novel single molecule hormone, which acts equally on the receptors of the insulin-stimulating hormones GLP-1 and GIP, was observed to reduce weight and improve blood sugar.

31 Oct 2013

NanoViricides’ FluCide drug candidate found to be well tolerated in non-GLP safety/toxicology study

NanoViricides, Inc. (the "Company") reports that its optimized injectable FluCide® drug candidate was found to be well tolerated in a non-GLP small animal safety/toxicology study. This study is an important step in the drug development pathway for FluCide.

21 Oct 2013

CHD Bioscience's lead product can help mitigate increasing threat of HAIs

According to a recent report issued by the Centers for Disease Control, every year more than two million people develop infections that are resistant to antibiotics. Specific healthcare-associated infections are classified as urgent threats and affect approximately 1.7 million people annually across the United States, leading to death in nearly 99,000 patients.

9 Oct 2013

Arrowhead initiates Phase 1 study of ARC-520 for treatment against chronic HBV infection

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it completed enrollment in a Phase 1 clinical trial of ARC-520, its RNAi-based candidate against chronic hepatitis B virus infection.

9 Oct 2013

Efficacy and safety data on linagliptin and investigational compound empagliflozin* in various diabetes subpopulations presented by Boehringer Ingelheim and Eli Lilly and Company

Boehringer Ingelheim and Eli Lilly and Company today announced they will feature five oral and 12 poster presentations for linagliptin and the investigational compound empagliflozin* at the 49th Annual Meeting of the European Association for the Study of Diabetes (EASD) which will take place in Barcelona, from 23 – 27 September. The presentations will add to the already existing body of data on safety and efficacy of these two compounds.

18 Sep 2013

Amino acid arginine improves treatment for type 2 diabetes

More than 371 million people worldwide suffer from diabetes, of whom 90% are affected by lifestyle-related diabetes mellitus type 2 (type 2 diabetes).

10 Sep 2013

Semaglutide News and Research

Latest Semaglutide News and Research

Isis Pharmaceuticals reports positive data from ISIS-GCGRRx Phase 2 study in patients with type 2 diabetes

Patients with Parkinson's disease show improvements after exenatide therapy

FDA approves GSK's Tanzeum as once-weekly treatment for type 2 diabetes

Common treatment for type 2 diabetes could cause longer-than-normal periods of hypoglycemia

Adocia announces positive final results for first clinical trial of BioChaperone Combo

New sweetener from tequila plant may aid diabetes, weight loss

DCR enters into agreement with Pyxant Labs for early clinical trials

Vivaldi Biosciences inks agreement with NIAID to evaluate LAIV candidates against influenza A

Macrophages invade diabetic pancreatic tissue during early stages of type 2 diabetes

Oramed Pharmaceuticals to purchase $15,800,000 shares in registered direct offering

Artificial sweetener sucralose has biological effects

Ascend, 3M partner to develop and evaluate novel immunotherapy treatments for cancer

GLP-1 hormone can predict metabolic efficacy of gastric bypass

New therapeutic approach for treating type 2 diabetes

Scientists develop new therapeutic approach for treatment of type 2 diabetes

NanoViricides’ FluCide drug candidate found to be well tolerated in non-GLP safety/toxicology study

CHD Bioscience's lead product can help mitigate increasing threat of HAIs

Arrowhead initiates Phase 1 study of ARC-520 for treatment against chronic HBV infection

Efficacy and safety data on linagliptin and investigational compound empagliflozin* in various diabetes subpopulations presented by Boehringer Ingelheim and Eli Lilly and Company

Amino acid arginine improves treatment for type 2 diabetes

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Semaglutide News and Research

Latest Semaglutide News and Research

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in